Navigation Links
Watson Completes Acquisition of Eden Biodesign
Date:1/28/2010

usiness. These factors include, among others, the difficulty of predicting the regulatory pathway, if any, to obtain FDA approval of generic or "biosimilar" biologic products; risks that competitors will seek to prevent Watson from obtaining FDA or other regulatory agency approval of biologic products through legislative, regulatory or other means; risks that the carrying values of assets may be negatively impacted by future events and circumstances; timely and successful consummation and implementation of strategic initiatives; the timing and success of product launches; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions; the uncertainty associated with the identification and successful consummation of external business development transactions; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson's and its third party manufacturers' facilities, products and/or businesses; periodic dependence on a small number of products for a material source of net revenue or income; changes in generally accepted accounting principles; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the period ended December 31, 2008 and quarterly report on Form 10-Q for the period ended September 30, 2009. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
2. Watson Files FDA Application for Generic Rozerem(R)
3. Watson to Present at Credit Suisse Healthcare Conference
4. Watson and Barr Settle Lawsuit Over Oxytrol(R)
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
7. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
8. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
9. Watson Launches Generic Biaxin(R) XL
10. World Heart Corp. Completes $7.3 Million Private Placement
11. Ethicon Completes Acquisition of Acclarent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... A global continuing medical education provider is ... in Central and South-East Asia ... dedicated to these diseases.      (Logo: http://photos.prnewswire.com/prnh/20150630/227090) ... Manage Hypertension Online and Manage Thyroid Online ... - combine the world,s top expertise with dynamic ...
(Date:7/3/2015)... 3, 2015 A global continuing ... diabetes and thyroid disorders in Latin America ... major conference dedicated to these diseases.      ... , Manage Hypertension Online and Manage ... EXCEMED - combine the world,s top expertise ...
(Date:7/3/2015)... July 3, 2015 Redwood Pharma ... Technologies Co., Ltd., operating in both the US and ... proprietary IntelliGel ® supramolecular hydrogel technology in its ... other ophthalmic therapies. The Broda technology offers many unique ... a free-forming liquid and with low concentrations of polymer ...
Breaking Medicine Technology:Combating Three Major Chronic Diseases in Central and South-East Asia With Medical Education 2Combating Three Major Chronic Diseases in Latin America With Medical Education 2Redwood Pharma Licenses Novel Hydrogel Drug Delivery Technology From Broda Technologies 2
... , - Used during coronary angioplasty plus stenting, ... a new reversible blood thinner did not have a ... of all-cause mortality, heart attack and need for new ... investigational drug significantly lessened the risk for two pre-specified ...
... Md., Nov. 13 The U.S. Food and Drug ... non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). ... to clot. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ... year by about 3 million U.S. women of reproductive ...
Cached Medicine Technology:American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis 2American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis 3FDA Approves Lysteda to Treat Heavy Menstrual Bleeding 2
(Date:7/6/2015)... ... ... MD Now, the leading and fastest-growing urgent care provider in Florida, opens ... serve residents and visitors in the Cutler Bay area, giving them convenient access to ... the new facility will be the fourth to serve Miami-Dade County. Located at 18851 ...
(Date:7/6/2015)... , ... July 06, 2015 , ... ... nearly $400,000 in grant funds to support a three-year effort to reduce rates ... work will be conducted in partnership with the Morehouse School of Medicine’s Prevention ...
(Date:7/6/2015)... , ... July 06, 2015 , ... ... today that Randstad Technologies selected Aspect Software Unified IP contact center solution hosted ... States, selected Aspect Unified IP as its future call center platform. , ...
(Date:7/6/2015)... ... July 06, 2015 , ... Thanks to donations and ... Hospice received the Music & Memory Certification for hospice patients and adult day center ... music not only to patients but also to their families and volunteers. Music & ...
(Date:7/5/2015)... ... ... City Sports, the Boston-based specialty sporting goods retailer, has renewed their partnership with ... summer with ethos, the owner and operator of the Boston Triathlon. , The first ... the North End Greenway. The event will help new triathletes prepare for the transition ...
Breaking Medicine News(10 mins):Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 2Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 3Health News:Georgia State, Morehouse Partner To Tackle Diabetes, Heart Disease In Atlanta’s Minority Communities 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 2Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 4Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 2Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 3
... $0.18 Earnings per Share, BILLERICA, Mass., Oct. 23 ... provider of precision technology and,semiconductor systems, today announced financial ... Third quarter revenue was $84.0 million, compared to $73.1 ... for the third quarter of 2006.,Excluding restructuring charges, operating ...
... Aflac Incorporated,today reported its third quarter results. Reflecting ... 5.1% to $3.9,billion during the third quarter of 2007, ... Net earnings were $420 million, or $.85 per diluted,share, ... year ago. Net,earnings included realized investment gains of $1 ...
... With the discovery of suitable molecular targets cellular ... cancer cells comes the perplexing dilemma of where ... and disable those targets. While the possibilities for drug ... and repositories are often problematic or ill-suited for the ...
... clay in unvented kilns could be a significant source ... periods, a new study suggests. , The results came ... the University of Michigan Dioxin Exposure Study, which measured ... River flood plain between Midland and Saginaw. , The ...
... SAN FRANCISCO -- Mayo Clinic today reported promising interim ... combination therapy for patients with recurrent ovarian cancer that ... participants achieved either complete or partial tumor regression from ... Findings from this Phase 2 Consortium (P2C) clinical trial ...
... Disorder Without Disturbing Patients, CHICAGO, Oct. 23 ... measuring airflow by nasal pressure, temperature, and/or carbon,dioxide, ... method is,uncomfortable to some and can potentially disturb ... 73rd annual international scientific assembly,of the American College ...
Cached Medicine News:Health News:GSI Group Reports Third Quarter Results 2Health News:GSI Group Reports Third Quarter Results 3Health News:GSI Group Reports Third Quarter Results 4Health News:GSI Group Reports Third Quarter Results 5Health News:GSI Group Reports Third Quarter Results 6Health News:GSI Group Reports Third Quarter Results 7Health News:GSI Group Reports Third Quarter Results 8Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 2Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 3Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 4Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 5Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 6Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 7Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 8Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 9Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 10Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 11Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 12Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 2Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 3Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 4Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 5Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 6Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 7Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 8Health News:Firing clay in unvented kilns may be a source of exposure to dioxins 2Health News:Mayo Clinic reports possible new therapy for patients with platinum-resistant ovarian cancer 2Health News:Infrared Imaging for Sleep Apnea Diagnosis Shows Promise 2Health News:Infrared Imaging for Sleep Apnea Diagnosis Shows Promise 3
Halle bone curette, 8 1/4, oval, malleable shaft, 4 mm wide....
Bruns bone curette, 9, oval, solid actagonal handle....
15" overall length, 9" handle....
9.5" overall length, 4.5" handle....
Medicine Products: